No Data
Jiahe Meikang (688246) 2024 third quarter report review: Q3 performance still under pressure, continuously enhancing product competitiveness with new technologies.
Summary of this report: The performance turned into a loss year-on-year due to multiple factors, falling short of expectations, continuously exploring the cni data factor index, AI applications to strengthen product competitiveness, and opening up more growth areas. Investment highlights: Maintain shareholding. The company's performance in the first three quarters fell short of expectations, considering...
Jiawumeikang (stock code: 688246): The competitive strength of fsg medical serv a AI products continues to strengthen.
The company released the third quarter report of 2024, achieving revenue of 0.476 billion yuan in the first three quarters, a year-on-year decrease of 11.52%, achieving a net income attributable to the parent company of -0.041 billion yuan, compared to a profit of 0.018 billion yuan in the same period last year. Among them, 24
Gwa Meikang Third Quarter Report 2024
Haitong International: The order for August has improved, with a recovery in medical IT demand.
In August, there was a significant improvement in the number and amount of large orders, indicating a strong demand for medical IT construction. The cumulative situation of winning bids in 2024 is stable.
Jiahe Meikang (688246): Computer Securities Research Report / Company Commentary
Investment event: The company released the interim report for 2024. The revenue scale reached 0.3 billion yuan, a year-on-year increase of 2.92%, and the net income attributable to the parent company was a loss of 0.027 billion yuan. Income grew slightly, and the gross margin improved. During the reporting period, the company's medical
Jiahe Meikang (688246): Short-term performance under pressure, AI medical large-scale model landing validation.
Investment Highlights: Event: The company released its 2024 interim report, achieving revenue of 0.3 billion yuan in 24H1, a year-on-year increase of 2.92%. Achieved net income attributable to shareholders of -0.027 billion yuan, compared to -0.023 billion in 23H1.
No Data
No Data